<DOC>
	<DOCNO>NCT01622231</DOCNO>
	<brief_summary>Safety GW685698X ( 55 µg/day , q.d . ) nasal spray period 12 week Japanese paediatric subject age 2 &lt; 15 year perennial allergic rhinitis evaluate . And secondarily , efficacy systemic exposure GW685698X ( 55 µg/day , q.d . ) nasal spray period 12 week Japanese paediatric subject age 2 &lt; 15 year perennial allergic rhinitis also evaluate .</brief_summary>
	<brief_title>Study FFR116365 , Open-label Study GW685698X Paediatric Subjects With Perennial Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Informed Consent 2 &lt; 15 year age , male eligible female ( female childbearing potential must commit consistent correct use acceptable method birth control ) , outpatient Diagnosis perennial allergic rhinitis : A positive test response house dust and/or dust mite serum antigenspecific IgE antibody test Visit 1 . Six month clinical history perennial allergic rhinitis . A positive test result nasal eosinophil count Visit 1/1A . Either subject 's parent/guardian sign ICF subject able complete assessment patient diary study . ALT &lt; 2xULN ; alkaline phosphatase bilirubin &lt; = 1.5xULN Average 3TNSS &gt; = 3.0 last consecutive 4 day prior Visit 2 . Completion patient diary &gt; = 3 day last consecutive 4 day prior Visit 2 Has seasonal pollen allergen A nose disorder could affect assessment study medication eye nose surgery ( within 3 month prior Visit 1 ) Bacterial viral infection upper respiratory tract eye Concurrent disease/abnormalities : Clinically significant uncontrolled disease Known hypersensitivity corticosteroid excipients investigational product Has recent participation study and/or exposure investigational study drug within 3 month prior Visit 1 Use follow medication and/or combination drug within specified time : AntiIgE ( Within 6 month prior Visit 1 ) , Immunosuppressive medication Systemic corticosteroid ( Within 8 week prior Visit 1 ) , Topical corticosteroid ( Within 4 week prior Visit 1 ) , Immunotherapy nonspecific allassotherapy initiate , discontinue change dose within 4 week prior Visit 1 Affiliation Investigator 's Site : Relative employee History alcohol drug abuse , child care opinion investigator ( subinvestigator ) , inappropriate enrol study . Bacterial viral infection upper respiratory tract eye screen period .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>